JP2024506595A5 - - Google Patents

Info

Publication number
JP2024506595A5
JP2024506595A5 JP2023547454A JP2023547454A JP2024506595A5 JP 2024506595 A5 JP2024506595 A5 JP 2024506595A5 JP 2023547454 A JP2023547454 A JP 2023547454A JP 2023547454 A JP2023547454 A JP 2023547454A JP 2024506595 A5 JP2024506595 A5 JP 2024506595A5
Authority
JP
Japan
Prior art keywords
ctn
pharmaceutical formulation
release
formulation according
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023547454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506595A (ja
JP7787190B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/007314 external-priority patent/WO2022181625A1/en
Publication of JP2024506595A publication Critical patent/JP2024506595A/ja
Publication of JP2024506595A5 publication Critical patent/JP2024506595A5/ja
Priority to JP2025134582A priority Critical patent/JP2025183214A/ja
Application granted granted Critical
Publication of JP7787190B2 publication Critical patent/JP7787190B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023547454A 2021-02-23 2022-02-22 センタナファジン製剤ならびにその製造および使用方法 Active JP7787190B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025134582A JP2025183214A (ja) 2021-02-23 2025-08-13 センタナファジン製剤ならびにその製造および使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163152826P 2021-02-23 2021-02-23
US63/152,826 2021-02-23
US202163241839P 2021-09-08 2021-09-08
US63/241,839 2021-09-08
PCT/JP2022/007314 WO2022181625A1 (en) 2021-02-23 2022-02-22 Centanafadine pharmaceutical formulations, and methods of making and using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025134582A Division JP2025183214A (ja) 2021-02-23 2025-08-13 センタナファジン製剤ならびにその製造および使用方法

Publications (3)

Publication Number Publication Date
JP2024506595A JP2024506595A (ja) 2024-02-14
JP2024506595A5 true JP2024506595A5 (cg-RX-API-DMAC7.html) 2024-05-31
JP7787190B2 JP7787190B2 (ja) 2025-12-16

Family

ID=80735736

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023547454A Active JP7787190B2 (ja) 2021-02-23 2022-02-22 センタナファジン製剤ならびにその製造および使用方法
JP2025134582A Pending JP2025183214A (ja) 2021-02-23 2025-08-13 センタナファジン製剤ならびにその製造および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025134582A Pending JP2025183214A (ja) 2021-02-23 2025-08-13 センタナファジン製剤ならびにその製造および使用方法

Country Status (11)

Country Link
US (6) US11564885B2 (cg-RX-API-DMAC7.html)
EP (1) EP4297734A1 (cg-RX-API-DMAC7.html)
JP (2) JP7787190B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230152046A (cg-RX-API-DMAC7.html)
AU (1) AU2022227367A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023015272A2 (cg-RX-API-DMAC7.html)
CA (1) CA3205786A1 (cg-RX-API-DMAC7.html)
IL (1) IL303767A (cg-RX-API-DMAC7.html)
MX (1) MX2023009833A (cg-RX-API-DMAC7.html)
TW (1) TW202302086A (cg-RX-API-DMAC7.html)
WO (1) WO2022181625A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202302086A (zh) * 2021-02-23 2023-01-16 日商大塚製藥股份有限公司 辛那法汀(Centanafadine)醫藥調配物、及其製造和使用方法
EP4577195A1 (en) * 2022-08-24 2025-07-02 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical composition comprising centanafadine
AU2023335210A1 (en) * 2022-09-02 2025-02-13 Otsuka Pharmaceutical Co., Ltd. 1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane for treating major depressive disorder
WO2025183181A1 (en) 2024-02-28 2025-09-04 Otsuka Pharmaceutical Co., Ltd. Use of centanafadine in treatment of adhd symptoms
US12502358B1 (en) 2024-08-13 2025-12-23 Innovate Therapeutics Llc Centanafadine multiphasic controlled-release pharmaceutical formulation
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
US6132724A (en) 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
WO2006133349A2 (en) 2005-06-08 2006-12-14 Alpharma, Inc. Orally disintegrable sleep aid formulations
ZA200801825B (en) 2005-07-27 2009-12-30 Dov Pharmaceutical Inc Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: Preparation and use to treat neuropsychiatric disorders
ES2529455T3 (es) * 2006-05-12 2015-02-20 Shire Llc Sistema de administración de fármacos por dosis controladas
US8846100B2 (en) * 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
RU2015106672A (ru) 2012-07-27 2016-09-20 УЭЛЛСЛИ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Фармацевтическая композиция для уменьшения частоты мочеиспускания и способ ее применения
EP3080080A4 (en) 2013-12-09 2017-08-16 Neurovance, Inc. Novel compositions
EP3069715A1 (en) * 2015-03-20 2016-09-21 Salmon Pharma GmbH Immediate release dosage forms of Atomoxetine
US20180008575A1 (en) 2016-07-11 2018-01-11 Neurovance, Inc. Methods of treating binge eating disorder
TW202302086A (zh) * 2021-02-23 2023-01-16 日商大塚製藥股份有限公司 辛那法汀(Centanafadine)醫藥調配物、及其製造和使用方法

Similar Documents

Publication Publication Date Title
US6156343A (en) Controlled release preparation
JP2002527468A (ja) 脈動用量薬剤経口送達システム
EP2205279B1 (en) Pharmaceutical combination of aliskiren and valsartan
US12370144B2 (en) Centanafadine pharmaceutical formulations, and methods of making and using same
JPH11502843A (ja) ジルチアゼム除放性製剤
JP2012144577A (ja) トロスピウムの1日1回剤形
US20080254112A1 (en) Pharmaceutical Active-Ingredient-Containing Formulation with Coating
JP2022531012A5 (cg-RX-API-DMAC7.html)
US8815285B2 (en) Extended release dosage forms of metoprolol
CN115721621A (zh) 一种依帕司他缓释制剂
US20090028944A1 (en) Pharmaceutical compositions comprising mesalamine
JP2025508321A5 (cg-RX-API-DMAC7.html)
TW202302116A (zh) 口服腸溶皮質類固醇的藥物組合物
CA2954474C (en) Capsule dosage form of metoprolol succinate
EP3331502A1 (en) Controlled release propiverine formulations
WO2009065130A2 (en) Modified release formulations of diltiazem
AU6224699A (en) Taste masking coating compositions
CA2433915A1 (en) Improved controlled release oral dosage form
JP5070618B2 (ja) 腸溶性顆粒剤及びその製造方法
TWI434682B (zh) 用以製備控制釋放口服劑型的配方及方法
WO2024162929A1 (en) A controlled release formulation of propiverine
EP4142694A1 (en) Novel multiparticulate pharmaceutical composition of tamsulosin and solifenacin
WO2009130712A2 (en) Controlled release pharmaceutical compositions of trospium
CN101052382A (zh) 用于制备含有丁氨苯丙酮的药学组合物的方法和制剂
JP2010155854A (ja) 持続性医薬製剤